Compare OMER & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMER | NBXG |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2008 | 2021 |
| Metric | OMER | NBXG |
|---|---|---|
| Price | $13.29 | $12.64 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $27.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 249.1K |
| Earning Date | 11-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $29,868,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $66.13 | N/A |
| P/E Ratio | $107.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.70 | $12.32 |
| 52 Week High | $21.24 | $17.43 |
| Indicator | OMER | NBXG |
|---|---|---|
| Relative Strength Index (RSI) | 30.78 | 28.51 |
| Support Level | $9.45 | $12.32 |
| Resistance Level | $19.68 | $15.83 |
| Average True Range (ATR) | 0.92 | 0.44 |
| MACD | -0.45 | -0.09 |
| Stochastic Oscillator | 8.90 | 3.54 |
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.